RCUS vs. MLTX, PTGX, DICE, KROS, DVAX, GMTX, AGIO, ZNTL, SNDX, and TARO
Should you be buying Arcus Biosciences stock or one of its competitors? The main competitors of Arcus Biosciences include MoonLake Immunotherapeutics (MLTX), Protagonist Therapeutics (PTGX), DICE Therapeutics (DICE), Keros Therapeutics (KROS), Dynavax Technologies (DVAX), Gemini Therapeutics (GMTX), Agios Pharmaceuticals (AGIO), Zentalis Pharmaceuticals (ZNTL), Syndax Pharmaceuticals (SNDX), and Taro Pharmaceutical Industries (TARO). These companies are all part of the "pharmaceutical preparations" industry.
Arcus Biosciences vs.
MoonLake Immunotherapeutics (NASDAQ:MLTX) and Arcus Biosciences (NYSE:RCUS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability, media sentiment and community ranking.
Arcus Biosciences received 153 more outperform votes than MoonLake Immunotherapeutics when rated by MarketBeat users. However, 83.33% of users gave MoonLake Immunotherapeutics an outperform vote while only 63.16% of users gave Arcus Biosciences an outperform vote.
MoonLake Immunotherapeutics has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500.
76.1% of MoonLake Immunotherapeutics shares are owned by institutional investors. Comparatively, 73.0% of Arcus Biosciences shares are owned by institutional investors. 15.3% of MoonLake Immunotherapeutics shares are owned by insiders. Comparatively, 13.8% of Arcus Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
MoonLake Immunotherapeutics has higher earnings, but lower revenue than Arcus Biosciences. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.
MoonLake Immunotherapeutics currently has a consensus price target of $25.29, suggesting a potential downside of 13.58%. Arcus Biosciences has a consensus price target of $41.44, suggesting a potential upside of 96.42%. Given Arcus Biosciences' higher possible upside, analysts clearly believe Arcus Biosciences is more favorable than MoonLake Immunotherapeutics.
MoonLake Immunotherapeutics has a net margin of 0.00% compared to Arcus Biosciences' net margin of -233.41%. Arcus Biosciences' return on equity of -41.22% beat MoonLake Immunotherapeutics' return on equity.
In the previous week, Arcus Biosciences had 5 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 6 mentions for Arcus Biosciences and 1 mentions for MoonLake Immunotherapeutics. Arcus Biosciences' average media sentiment score of 0.36 beat MoonLake Immunotherapeutics' score of 0.00 indicating that Arcus Biosciences is being referred to more favorably in the news media.
Summary
MoonLake Immunotherapeutics beats Arcus Biosciences on 9 of the 17 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RCUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arcus Biosciences Competitors List
Related Companies and Tools
